Department of Gastroenterology, Putuo People's Hospital, Tongji University School of Medicine, Shanghai, 200060, China; Department of Gastroenterology, Shanghai Tenth People'sHospital, Tongji University School of Medicine, Shanghai, 200072, China.
Department of Gastroenterology, Shanghai Tenth People'sHospital, Tongji University School of Medicine, Shanghai, 200072, China.
Biomed Pharmacother. 2021 Apr;136:111255. doi: 10.1016/j.biopha.2021.111255. Epub 2021 Jan 20.
Nonalcoholic fatty liver disease (NAFLD) has become the most common liver disorder in both China and worldwide. It ranges from simple steatosis and progresses over time to nonalcoholic steatohepatitis (NASH), advanced liver fibrosis, cirrhosis, or hepatocellular carcinoma(HCC). Furthermore, NAFLD and its complications impose a huge health burden to society. The microbiota is widely connected and plays an active role in human physiology and pathology, and it is a hidden 'organ' in determining the state of the host, in terms of homeostasis, or disease. Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptorsuperfamily and can regulate multiple pathways involved in metabolism, and serve as effective targets forthe treatment of many types of metabolic syndromes, including NAFLD. The purpose of this review is to integrate related articles on gut microbiota, PPARs and NAFLD, and present a balanced overview on how the microbiota can possibly influence the development of NAFLD through PPARs.
非酒精性脂肪性肝病（NAFLD）已成为中、全球范围内最常见的肝脏疾病。它从轻度单纯性脂肪变性发展，随着时间的推移进展为非酒精性脂肪性肝炎（NASH）、进展性肝纤维化、肝硬化或肝细胞癌（HCC）。此外，NAFLD 及其并发症给社会带来了巨大的健康负担。微生物群广泛相连，并在人类生理学和病理学中发挥积极作用，它是决定宿主状态的隐藏“器官”，无论是在稳态还是疾病方面。过氧化物酶体增殖物激活受体（PPARs）是核受体超家族的成员，可调节参与代谢的多种途径，是治疗多种代谢综合征（包括 NAFLD）的有效靶点。本综述的目的是整合有关肠道微生物群、PPARs 和 NAFLD 的相关文章，并就微生物群如何通过 PPARs 影响 NAFLD 的发展提供平衡的概述。
